Diagnostic and prognostic advancement combined with innovative approaches towards therapeutic vaccinations and drugs for community-acquired pneumonia (CAP) treatment and cure is massively urging demand in the global market. Epidemiological research by government organizations and propounding of novel solutions for pneumonia by major pharmaceutical companies is leading to developments in the test screening of CAP. Frequent incidences of comorbidity risks of CAP necessitate adequate and immediate treatment which is limited in remote locations, and is thereby carving new opportunities for community-acquired pneumonia market growth and development.

Globally, pneumonia accounted for around 880,000 children death occurrences in the year 2016.

- United Nations Children's Fund (UNICEF)

Artificial Intelligence (AI) integrated chest X-ray is a major breakthrough for CAP diagnosis procedures with lesser time consumption for radiograph assessment, which will significantly aid the community-acquired pneumonia market demand in future years. The global Community Acquired Pneumonia Market is estimated to generate $4.9 billion as of 2018 with a demand pull inflation, which will lead the market to grow with 8.1% CAGR during the forecast period of 2019-2025. Biomarker and bacterial resistant antibiotic evolution offer multitudes of opportunity for the CAP drugs and diagnosis market to flourish and generate huge demand from across the world. Most commonly occurring during the neonatal period, CAP requires effective treatment procedures such as endotracheal intubation. The application of CAP medication in newborns is projected to generate huge demand, which will grow considerably at a CAGR of 8.4% through to 2025.

APAC is leading the global CAP market with a major share of 42% in 2018. Facilitated by an increasing birth rate and a large population count, the risk of CAP and comorbidity incidences is higher in this region. Asian population is ageing at a faster pace indicative of the rising susceptibility to health deterioration and ailments. According to the Asian Development Bank, the total geriatric population is anticipated to reach 923 million by the middle of the 21st century. This suggests that there is a higher probability of the occurrences of CAP in this region, which will escalate demand for treatment procedures and diagnosis tests of CAP over the due course of time. With increasing infrastructural expansion and industrial establishment over the past many decades, the air quality is rapidly deteriorating in Asian territory which contributes largely to the increasing CAP incidences. A total of 92% of the APAC population, which equals 4 billion people, are prone to high air toxicity, as per the Climate & Clean Air Coalition, signifying an immense rise in CAP and associated growth prospects for the CAP market in the APAC region.

Causative Factors and Government Initiatives:

With adequate prevention steps and proper treatment, nearly 5.3 million lives can be saved by the year 2030.

-       Save the Children

High Risk of Associated Morbidity:

CAP is a major concern in several countries owing to the higher incidences of fatality associated with comorbidity risks such as sepsis, dyspnea, pleural effusion, and abscess and severity other conditions in pediatric and geriatric population. Majorly aggravated by asthma and chronic obstructive pulmonary disease (COPD), complications related to CAP pose serious health and life risks which is propelling high demand for CAP drugs and treatment procedure. According to the American Academy of Allergy, Asthma & Immunology (AAAAI), nearly 8.3% of the children in the U.S. suffered from asthma in 2016. This is indicative of the asthma-induced CAP risk and the need for its management and diagnosis eventually influencing the community acquired disease market demand. COPD stimulates the risk of developing CAP, thereby compelling a need for advanced healthcare treatment procedures to minimize the risk of life-threatening consequences, pushing forth the global CAP market growth.

Annually, around 250,000 community acquired pneumonia affected people are hospitalized in Germany.

-       National Center for Biotechnology Information (NCBI)

Severity of CAP emphasizes an increase in obtaining healthcare services which leads to increased CAP market demand and increase in the overall revenue generation boosted by extensive medical expenditure. Major diagnosis of pneumonia accounts for approximately 257,000 hospital visits to the emergency section in the hospitals, which is reflective of the medical expenses for treatment and identification of health risks in the U.S.

Support Actions Encouraged by Organizations:

Government health initiative programs assisted by non-profit organizations and several companies are prime expedite to the CAP market growth. The ‘Stop Pneumonia’ program campaigns to aid pneumonia-affected children in 15 countries with major death rates due to pneumonia and diarrhea. Clinton Health Access Initiative (CHAI), in collaboration with IKEA and the government, works progressively towards reducing pneumonia complications and death incidences in several countries by dispersing Amoxicillin Dispersible tablets, pulse oximeters, and other imperative treatment necessities. Furthermore, Gavi supports the global cause by providing vaccines and antibiotics working unitedly with the Save the Children organization, and the demand for vaccine doses in Gavi supported countries is estimated to reach 260 million doses by 2026. This signifies the increasing opportunities for the global CAP market growth and huge R&D prospects in forthcoming years.

Disruptive CAP Treatment Innovations:

Modern advances and novel treatment procedures introduced in the global CAP market offers significant solutions to the increasing CAP and comorbidity risks throughout the world which is majorly accelerated by the reduced air quality in several nations.

Recently, Melinta Therapeutics introduced BAXDELA®, a new CAP drug approved by the U.S. Food and Drug Administration (FDA) for treating community acquired bacterial pneumonia (CABP) which is likely to deliver medication for the antibiotic resistant bacteria. A recent research study highlights that CAL02 Treatment is helpful in addressing the severe pneumococcal pneumonia, which makes it a disruptive innovation in the global community acquired pneumonia market.

TimeZero™ Legionella tests launched by Phigenics is a breakthrough in detecting the legionella pathogens which triggers bacterial pneumonia worldwide. Another revolutionary research conducted by Technical University of Munich (TUM) proffers a 35 minutes diagnostic test for legionella detection with the help of LegioTyper chip, unlike the conventional 10-14 days cell culture method. In the line of major advancements, the production and release of new drugs such as Lefamulin, Solithromycin, Nemonoxacin, Omadacycline for effective treatment of CAP in the global market remains a major factor for elevating CAP market growth and demand in future years.

Key Developments Propelled By Leading Companies:

Innovation is an imperative sustenance demand in the competitive market landscape supported by the development of various novel solutions to gain surplus economic income and uphold the individual brand image. Companies such as KYORIN Pharmaceutical Co., Ltd., C10 Pharma A/S, Biotest AG, Merck & Co., Melinta Therapeutics, BioAegis Therapeutics, Inc., AstraZeneca plc, and Pfizer Inc., deliver several drugs and healthcare solutions for CAP morbidity treatment trendsetting developmental progresses for nascent companies in this market.

Biotest AG is a biotechnology-based medical service provider company with prominent pipeline innovation contributing largely to the CAP therapeutic development and advancement, and launched Trimodulin BT-588 as a major drug for treatment of severe community acquired pneumonia (sCAP). Pfizer Inc. launched revolutionary products for CAP treatment which includes plasma gelsolin (pGSN) therapy with prime approach towards inhibiting pathogen growth, consequently reducing inflammation and infection. Pfizer also announced the conduction of 20-valent pneumococcal conjugate vaccine (20vPnC) Phase 3 Program which will offer breakthroughs in limiting growth of sCAP, which will be a major boost to the modern CAP treatment market in the forthcoming years.

Talk to one of our sales representative about the full report by providing your details in the link below:


Related Reports:

A.    Legionella Testing Market


B.     Tigecycline Market


C.    Infection prevention & Control Market


Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.

To request for a quote, provide your details in the below link:


Media Contact:

Mr. Venkat Reddy

Sales Manager          

Email: [email protected]

Contact Sales: +1-614-588-8538 (Ext-101)

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.